Rapport Therapeutics, Common Stock Today

RAPP Stock   12.69  0.18  1.44%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 50

 
High
 
Low
About Average
Rapport Therapeutics, is selling at 12.69 as of the 18th of January 2025; that is 1.44 percent up since the beginning of the trading day. The stock's last reported lowest price was 12.52. Rapport Therapeutics, has 50 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 20th of October 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of June 2024
Category
Healthcare
Classification
Health Care
Rapport Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 36.58 M outstanding shares of which 1.77 M shares are at this time shorted by private and institutional investors with about 11.75 trading days to cover. More on Rapport Therapeutics, Common

Moving together with Rapport Stock

  0.61EQ EquilliumPairCorr
  0.66ME 23Andme HoldingPairCorr
  0.66VALN Valneva SE ADRPairCorr

Moving against Rapport Stock

  0.91DRTS Alpha Tau MedicalPairCorr
  0.78SRZNW Surrozen WarrantPairCorr
  0.7DMAC DiaMedica TherapeuticsPairCorr
  0.69VCEL Vericel Corp OrdPairCorr
  0.68CDIOW Cardio DiagnosticsPairCorr
  0.68SABSW SAB BiotherapeuticsPairCorr

Rapport Stock Highlights

ESG Sustainability
58.6%
Environmental
61.6%
Governance
Social
President CEOAbraham MBA
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities5.8 M10.1 M
Way Down
Slightly volatile
Non Current Liabilities Total6.4 M5.1 M
Significantly Up
Slightly volatile
Total Assets102.9 M178.7 M
Way Down
Slightly volatile
Total Current Assets100.2 M173.5 M
Way Down
Slightly volatile
Rapport Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rapport Therapeutics,'s financial leverage. It provides some insight into what part of Rapport Therapeutics,'s total assets is financed by creditors.
Rapport Therapeutics, Common (RAPP) is traded on NASDAQ Exchange in USA. It is located in 1325 Boylston Street, Boston, MA, United States, 02215 and employs 11 people. Rapport Therapeutics, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 762.25 M. Rapport Therapeutics, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 36.58 M outstanding shares of which 1.77 M shares are at this time shorted by private and institutional investors with about 11.75 trading days to cover. Rapport Therapeutics, generates negative cash flow from operations
Check Rapport Therapeutics, Probability Of Bankruptcy
Ownership Allocation
The majority of Rapport Therapeutics, Common outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rapport Therapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rapport Therapeutics,. Please pay attention to any change in the institutional holdings of Rapport Therapeutics, as this could imply that something significant has changed or is about to change at the company.
Check Rapport Ownership Details

Rapport Therapeutics, Historical Income Statement

View More Fundamentals

Rapport Stock Against Markets

Rapport Therapeutics, Corporate Management

Troy IgnelziChief OfficerProfile
Bradley MDChief OfficerProfile
Cheryl GaultChief OfficerProfile
Swamy YeleswaramChief OfficerProfile
Arnold PharmDSenior AffairsProfile

Additional Tools for Rapport Stock Analysis

When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.